Syndax Pharmaceuticals, Inc.
SNDXSyndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. The company is known for its use of epigenetic modulators, particularly histone deacetylase (HDAC) inhibitors, to enhance the effectiveness of immunotherapies and targeted treatments. Syndax's lead investigational drug, Axzagertib (formerly Entinostat), aims to improve outcomes in various cancers by modulating the tumor microenvironment and overcoming resistance mechanisms.
Company News
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and management team will participate in three major investor conferences in May-June 2026: TD Cowen 7th Annual Oncology Innovation Summit (May 27), Jefferies Global Healthcare Conference (June 4), and Goldman Sachs 47th Annual Global Healthcare Conference (June 8). Live webcasts will be...
Sphera Funds Management Ltd. invested $6.54 million in Syndax Pharmaceuticals by purchasing 374,847 shares in Q4 2025. Syndax has demonstrated strong commercial traction with two approved therapies generating $172.4 million in annual revenue, up significantly from $23.7 million the prior year. The stock has surged over 80% in the past year, refle...
Syndax Pharmaceuticals and the World Orphan Drug Alliance announced a collaboration to expand access to Revuforj (revumenib), a first-in-class menin inhibitor, through a Managed Access Program in regions including parts of Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa where the drug is not yet c...
Syndax Pharmaceuticals' CEO will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, discussing the company's innovative cancer therapies and pipeline developments.
The FDA approved Revuforj (revumenib) for treating relapsed or refractory acute myeloid leukemia with NPM1 mutation in adult and pediatric patients, marking the first and only therapy approved for multiple acute leukemia subtypes.
